Mevidalen

Mevidalen
Clinical data
Other namesLY-3154207; LY3154207
Identifiers
IUPAC name
  • 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC24H29Cl2NO3
Molar mass450.40 g·mol−1
3D model (JSmol)
SMILES
  • C[C@H]1C2=CC=CC(=C2C[C@@H](N1C(=O)CC3=C(C=CC=C3Cl)Cl)CO)CCC(C)(C)O
InChI
  • InChI=1S/C24H29Cl2NO3/c1-15-18-7-4-6-16(10-11-24(2,3)30)19(18)12-17(14-28)27(15)23(29)13-20-21(25)8-5-9-22(20)26/h4-9,15,17,28,30H,10-14H2,1-3H3/t15-,17+/m0/s1
  • Key:XHCSBQBBGNQINS-DOTOQJQBSA-N

Mevidalen (developmental code name LY-3154207) is a dopaminergic drug which is under development for the treatment of Lewy body disease, including those with Parkinson's disease.[1][2][3][4][5] It acts as a selective positive allosteric modulator (PAM) of the dopamine D1 receptor.[1][6] The drug is orally active and crosses the blood–brain barrier.[6] It is a tetrahydroisoquinoline and is a close analogue of DETQ, another D1 receptor PAM.[2][3][6] Mevidalen has been found to have wakefulness-promoting effects in sleep-deprived humans.[7][8] Side effects of mevidalen have been reported to include increased heart rate and blood pressure, insomnia, dizziness, nausea, vomiting, anxiety, nervousness, fatigue, headaches, palpitations, and contact dermatitis, as well as falls in those with dementia.[6][5][8] As of March 2022, mevidalen is in phase 2 clinical trials for the treatment of Lewy body disease.[1] Besides for movement disorders and dementia, D1 receptor PAMs like mevidalen might have value in the treatment of certain neuropsychiatric disorders, such as depression, excessive somnolence, and attention deficit hyperactivity disorder.[2]

References

  1. 1 2 3 "Mevidalen - Eli Lilly and Company - AdisInsight".
  2. 1 2 3 Svensson, Kjell A.; Hao, Junliang; Bruns, Robert F. (2019). "Positive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disorders". Advances in Pharmacology. Advances in Pharmacology (San Diego, Calif.). Vol. 86. Elsevier. pp. 273–305. doi:10.1016/bs.apha.2019.06.001. ISBN 9780128166680. ISSN 1054-3589. PMID 31378255. S2CID 199071223.
  3. 1 2 Hao J, Beck J, Zhou X, Lackner GL, Johnston R, Reinhard M, Goldsmith P, Hollinshead S, Dehlinger V, Filla SA, Wang XS, Richardson J, Posada M, Mohutsky M, Schober D, Katner JS, Chen Q, Hu B, Remick DM, Coates DA, Mathes BM, Hawk MK, Svensson KA, Hembre E (March 2022). "Synthesis and Preclinical Characterization of LY3154885, a Human Dopamine D1 Receptor Positive Allosteric Modulator with an Improved Nonclinical Drug-Drug Interaction Risk Profile". J Med Chem. 65 (5): 3786–3797. doi:10.1021/acs.jmedchem.1c01887. PMID 35175768. S2CID 246942987.
  4. ↑ Biglan K, Munsie L, Svensson KA, Ardayfio P, Pugh M, Sims J, Brys M (March 2022). "Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo-Controlled Trial". Mov Disord. 37 (3): 513–524. doi:10.1002/mds.28879. PMID 34859493. S2CID 244887088.
  5. 1 2 Wilbraham D, Biglan KM, Svensson KA, Tsai M, Pugh M, Ardayfio P, Kielbasa W (March 2022). "Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor-Positive Allosteric Modulator, in Patients With Parkinson Disease". Clin Pharmacol Drug Dev. 11 (3): 324–332. doi:10.1002/cpdd.1039. PMID 34664427. S2CID 239028000.
  6. 1 2 3 4 Wilbraham D, Biglan KM, Svensson KA, Tsai M, Kielbasa W (April 2021). "Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor-Positive Allosteric Modulator (D1PAM), in Healthy Subjects". Clin Pharmacol Drug Dev. 10 (4): 393–403. doi:10.1002/cpdd.874. PMC 8048550. PMID 33029934.
  7. ↑ Jones-Tabah J, Mohammad H, Paulus EG, Clarke PB, Hébert TE (2021). "The Signaling and Pharmacology of the Dopamine D1 Receptor". Front Cell Neurosci. 15: 806618. doi:10.3389/fncel.2021.806618. PMC 8801442. PMID 35110997.
  8. 1 2 McCarthy AP, Svensson KA, Shanks E, Brittain C, Eastwood BJ, Kielbasa W, Biglan KM, Wafford KA (March 2022). "The Dopamine D1 Receptor Positive Allosteric Modulator Mevidalen (LY3154207) Enhances Wakefulness in the Humanized D1 Mouse and in Sleep-Deprived Healthy Male Volunteers". J Pharmacol Exp Ther. 380 (3): 143–152. doi:10.1124/jpet.121.000719. PMID 34893551. S2CID 247363215.



This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.